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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
Primary
Effectiveness of antacids, sucralfate and bismuth salts in reducing overall functional dyspepsia symptoms in dyspeptic people.
Secondary
1. Quality of life
2. Individual dyspepsia symptom change
3. Adverse events and complications
B A C K G R O U N D
Description of the condition
Functional (or non-ulcer) dyspepsia (FD) is characterized by the
presence of one or more of the following items: epigastric (over the
stomach) pain or burning, postprandial (occurring after a meal)
epigastric fullness sensation, early satiation or complaint of inabil-
ity to finish a regular meal, with no anatomical abnormality (de-
tected by gastroscopy, an examination of the upper digestive tract
using a long, thin, flexible tube containing a camera and a light
to view the lining of these organs) or routinely detectable motility
(contraction of the muscles) disorder to explain the symptoms. In
reference to the Rome III criteria, these items should be present
for the last three months with symptom onset at least six months
before diagnosis (Kourikou 2015).The prevalence of FD differs
between 5% to 40%, depending on geographical area and vari-
ation in definition criteria (Amini 2012; Lacy 2013; Mahadeva
2016).
Several factors have been demonstrated as the pathophysiologic
(the abnormal physical states that accompany a disease) aspects
of FD such as alterations in gastric acid secretion, gastroduodenal
dysmotility (relating to the stomach and intestines, impaired mus-
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cle), visceral hypersensitivity (excessive pain sensitivity in internal
organs) Helicobacter pylori infection, genetics and psychological
elements (Moayyedi 2011; Overland 2014).
Functional dyspepsia has been associated with several genetic
polymorphisms (occurring in several different forms) (G-protein
B3, serotonin transporter promoter, interlukin-17F, migration in-
hibitory factor, cholecystocynine-1; intron 1, cyclooxygenase-1,
catechol-O-methyl-transferase, transient receptor potential vanil-
loid1 receptor, regulated upon activation normal T cell expressed
and secreted, p22 PHOX, Toll like receptor 2, SCN10 A, CD14
and adrenoreceptors) that play a role in visceral hypersensitivity
and other upper abdominal symptoms (Kourikou 2015; Overland
2014). Moreover, history of acute infectious gastroenteritis is an-
other factor that suggested patients with FD are slower, or unable,
to terminate the inflammatory response (Overland 2014).
Anxiety, chronic tension, hostility, and hypochondriasis are more
common in patients with FD compared with the normal popu-
lation (Hallissey 1987). Fifty per cent of Europeans and North
Americans and two-thirds of patients who had consulted a physi-
cian were receiving medication for their dyspepsia (Overland
2014). Also, due to burdensome symptoms, more than 30% of
patients miss work or school hours (Mahadeva 2016; Overland
2014). The clinical management of functional dyspepsia, in view
of the unknown cause and poorly understood pathophysiology, is
still controversial.
Description of the intervention
Since various pathophysiological factors for FD seem to in-
teract, several treatment modalities including pharmacological
or nonpharmacological have been suggested in its management
(Talley 1991; Talley 1995). Pharmacological treatment includes
H2 -receptor antagonists (Bekhti 1979; Holtmann 2002; Talley
1998; Van Outryve 1993), proton pump inhibitors (McColl
1998; Wong 2002), Helicobacter pylori eradication therapy (Blum
1998; Froehlich 2001; Hamilton 2000; Talley 1998; Talley
1999), and even antidepressants or psychological interventions
(Bolling-Sternevald 2003; Calvert 2002).
Other treatment modalities may also be important. Bismuth salts
were more effective than placebo for the treatment of functional
dyspepsia (Moayyedi 2006). Themajority of studies suggested that
bismuth was efficacious to assessH.pylori eradication in functional
dyspepsia (Moayyedi 2006; Talley 2005). In view of the fact that
bismuth salts have been associated with neurotoxicity (damage to
the brain and nervous system by a poisonous substance) when
used long term, this prescription was not recommended as a first-
line therapy. The outcomes of treatment with sucralfate for FD
are also controversial. Some trials demonstrated that sucralfate
improved FD symptoms, but it seems that there is little evidence
of comparisons of placebo with sucralfate (Moayyedi 2006; Talley
2005). Evaluation for the efficacy of antacids was done in small
patient cohorts, but no evidence was identified that compared
antacids with placebo for FD treatment. Antacids are routinely
used, but there is a lack of strong evidence for its effectiveness
(Overland 2014).
How the intervention might work
Antacids reduce acid-related symptoms such as abdominal pain
(especially fasting pain) and burning sensations (Chen 2013).
Antacids alsomay increase angiogenesis (the formation of different
blood vessels), they bind bile acid and also inhibit peptic (relating
to digestion) activity. Also, the heavy metals aluminum and mag-
nesium hydroxide decreased peptic activity but did not eradicate
H.pylori.
Antacids containing magnesium cause diarrhoea and hypermag-
nesaemia; the latter only becomes important in patients with renal
insufficiency. Amounts of calcium and alkali, particularly calcium
carbonate, can result in hypercalcaemia, alkalosis, and acute or
chronic renal injury, known as the milk-alkali syndrome (Orwoll
1982). Significant aluminium retention occurs in patients with
renal failure and may lead to neurotoxicity and anaemia following
prolonged treatment with aluminium hydroxide (Shields 1978a).
Sucralfate improves acid-related symptoms and dysmotility-like
symptoms in FD. Also sucralfate stimulates angiogenesis and the
formation of granulation tissue (material formed in repair of
wounds of soft tissue), due to growth factor binding. Moreover,
sucralfate suppresses H.pylori and inhibits acid secretion and de-
creases symptoms in some patients. Adverse effects of sucralfate
are few (Soll 1991). Constipation may occur in 2% patients and,
similar to antacids, aluminium retention in patients with renal
failure is possible.
Bismuth can suppress H.pylori and this may indicate its appro-
priateness for FD. Also bismuth inhibits peptic activity, but not
pepsin release or gastric acid secretion.
Why it is important to do this review
During the last decade, several published systematic reviews and
meta-analyses have recommended different treatments for func-
tional dyspepsia such as antacids, sucralfate and bismuth salts
(Hansen 1998; Moayyedi 2006; Moayyedi 2011; Suzuki 2011).
Since then, several RCTs were published that investigated the effi-
cacy of these drugs, but no systematic reviews assessed these studies
and a previous Cochrane systematic review has been withdrawn
(Moayyedi 2011).
Antacid, sucralfate and bismuth could decrease the stimulating
factors that may make positive effects on FD. Also antacids, su-
cralfate and bismuth salts are available without prescription, and
are inexpensive. Since functional dyspepsia is a recurrent disorder,
and these drugs are widely available, they appear to be easy to use
remedy options. Evidence for the real efficacy of these drugs in
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functional dyspepsia will help physicians to understand when to
prescribe them or avoid their use altogether.
O B J E C T I V E S
Primary
Effectiveness of antacids, sucralfate and bismuth salts in reducing
overall functional dyspepsia symptoms in dyspeptic people.
Secondary
1. Quality of life
2. Individual dyspepsia symptom change
3. Adverse events and complications
M E T H O D S
Criteria for considering studies for this review
Types of studies
All experimental or interventional studies, without any limitation
in type and details, that studied the effectiveness of three classes of
drugs (antacids, sucralfate and bismuth salts) in the improvement
of either individual or global dyspepsia.
Types of participants
We will include all participants over 18 years, of both genders,
with a diagnosis of functional dyspepsia (functional or non-ulcer
dyspepsia) according to any well-defined criteria (such as Rome I,
II, III , IV or Lancet Working Group) .
Studies that included other gastrointestinal diseases, such as peptic
ulcer, organic dyspepsia and reflux disease will be excluded.
This may be confirmed by checking if upper gastrointestinal en-
doscopy or any other diagnostic modality was performed in par-
ticipant recruitment for the study.
If a study included populations with different conditions, we will
only include participants with functional dyspepsia.
Participants in the trials that did not have any positive findings at
endoscopy or barium study, symptoms of hiatus hernia, less than
five gastric erosions or mild duodenitis will be included. We will
include all participants, naive or with a history of treatment of FD
and we will include all types of participant that were recruited in
studies such as participants in primary care, secondary or tertiary
care, or convenience sample.
Types of interventions
We will include trials comparing oral administration of any dose
of any available drug (antacids, sucralfate and bismuth salts) with
placebo.
Types of outcome measures
Outcomes in FD may be measured by an ordinal or dichotomous
(improved/not improved) scale. In ordinal measures, such as the
five-point Likert scale, we will assume that they are continuous
measures or variables and, for interpretation, we will use standard-
ized mean differences.
In ordinal scales with a variety of answers, we will assume that
scores above themean are improved and those lower than themean
are not improved.
Primary outcomes
Effectiveness of the three classes of drugs (antacids, sucralfate and
bismuth salts) in reducing overall functional dyspepsia symptoms.
Secondary outcomes
1. Quality of life score increment
2. Individual dyspepsia symptoms score reduction or
disappearance
3. Adverse events
Time (duration of therapy)
We will consider interventions of at least four weeks duration
(studies with outcome assessment carried out at less than four
weeks will be excluded). The outcome measures will be considered
mainly at the end of four weeks.
Search methods for identification of studies
Electronic searches
We will conduct a comprehensive literature search to identify
all published and unpublished randomised controlled trials with
no language restriction. We will search the following electronic
databases to identify potential studies:
• Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library) Appendix 1;
• MEDLINE 1966 to present Appendix 2; and
• Embase 1980 to present Appendix 3.
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Independent reviewers also will conduct a search for ongoing trials
on theClinicalTrials.gov (clinicaltrials.gov) andWorldHealthOr-
ganization International Clinical Trials Registry Platform (WHO
ICTRP) (apps.who.int/trialsearch). For grey literature we will
search in SIGLE (System for Information on Grey Literature
in Europe) (www.cf.ac.uk/insrv/eresources/databases/sigle.html)
and New York Academic of Medline Library Grey literature col-
lection (www.nyam.org/library/pages/grey_literature_report).
Searching other resources
We will handsearch the published abstracts from the conference
proceedings in United European Gastroenterology Week (pub-
lished in Gut) from 2005 to 2016. We will handsearch references
cited in studies found by the above search to identify further rele-
vant trials.
Data collection and analysis
Selection of studies
Two independent reviewers will screen the titles and abstracts of
papers to assess the eligibility for inclusion in the review. We will
document study selection or exclusion and create a list of stud-
ies to be included in the analysis. We will resolve any disagree-
ment through discussion or, if required, we will consult a third
person (PA). Information on study design, participant character-
istics, measurement of FD, adjustment for potential confounders,
and estimates of associations will be extracted independently by
two reviewers. Discrepancies will be resolved by discussion. We
will estimate the agreement level for all steps: title, abstract and
full-text screening and data extraction by discussion and reach a
consensus.
We will use Endnote to collect and manage citations. Since there
may be several published papers with the same result, we will
exclude duplicate and similar results and collate all results. Process
of study selections will be presented in PRISMA diagram form
and we will clarify the characteristics of excluded studies.
Data extraction and management
Datawill be extracted independently using a standard form (which
has been piloted by at least one study) by two reviewers to record
study characteristics and outcome data. Consensus will be used
for inconsistencies between authors. All numeric data from tables,
graphs or figures will be confirmed by a second reviewer. In the
case of missing data in the included studies, investigators will be
contacted (by email, letter and/or fax, phone) to prepare the miss-
ing information.
Two review authors will extract the following study characteristics
from the included studies:
1. Methods: study design, total duration of study and run-in,
number of study centres and location, study setting,
withdrawals, date of study.
2. Participants: number of participants, mean age, age range,
gender, severity of condition, diagnostic criteria, inclusion
criteria, exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, excluded medications (with or without placebo)
and duration of treatment and follow-up time.
4. Outcomes: primary and secondary outcomes specified and
collected, with time points reported.
Notes: Funding for trial, notable conflicts of interest of trial au-
thors, name of the author, year of publication, location/country
and ethics approval.
Assessment of risk of bias in included studies
Methodological quality will be assessed independently by at least
two review authors according to the Cochrane Handbook for Sys-
tematic Reviews of Interventions and Cochrane Review guidelines,
for each key outcome variable. Review authors will independently
assess the risk of bias within each included study based on the fol-
lowing domains with ratings of ‘Yes’ (low risk of bias); ‘No’ (high
risk of bias) and ‘Unclear’ (uncertain risk of bias):
• Sequence generation;
• Allocation concealment;
• Blinding (we will collect blinding information by
individually identifying the person blinded: single-blind, double-
blind and triple-blind);
• Incomplete outcome data;
• Selective outcome reporting.
We will use RevMan software for creation of a ’risk of bias’ table.
Also, we will create two types of figures with RevMan software for
clarifying the risk of bias:
1. A ’Risk of bias’ graph, which demonstrates the proportion
of studies complying with each of the judgments (’low’, ’high’
and ’unclear’ risk of bias); and
2. A ’Risk of bias’ summary, which shows all of the judgments
in a cross-tabulation of study by entry.
Measures of treatment effect
Analysis of dichotomous data will be recorded as risk ratio (RR)
and continuous data as mean difference (MD) or standardized
mean difference (SMD). Comparison of binary data will be re-
ported as a RR with an associated 95% confidence interval (CI),
an absolute risk reduction (ARR) or the number needed to treat
to benefit (NNTB) with associated 95% CI, or the Chi² test with
associated P value. We will collect continuous outcome data (dys-
pepsia score and quality of life) in three different ways:
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1. Unit of measurement or, if unit of measurement cannot be
reported (i.e. visual analogue scale), we will consider the data to
be unit-less.
2. Measure of central tendency: mean, median, mode.
3. Measure of variance, such as standard deviation, standard
error, interquartile range or 95% CI. If raw data are not
accessible, we will report the individual study analysis.
Continuous data measures will be collected after treatment.
Change scores will also be collected (the difference between scores
before and after intervention) for comparison. We will under-
take meta-analyses only where this is meaningful, i.e. if the treat-
ments, participants and the underlying clinical question are similar
enough for pooling to make sense. If the study reported median or
inter-quartile range, it is reasonable to assume that the data were
skewed. If we suspect the data is skewed, we will exclude stud-
ies that do not contain mean and standard deviation; otherwise,
median and interquartile range will be used instead of mean and
standard deviation, respectively. Where several intervention arms
were included in a single study, we will consider only the relevant
arms. If two arms of trial were compared to a single placebo group,
but reported separately in the text, to avoid double counting in a
single meta-analysis, we will halve the placebo number.
Unit of analysis issues
To reduce the possibility of unit of analysis error, we will take into
account the level at which randomisation occurred.
If we face trials with cluster randomizations, we may include each
participant as a case in general analysis, but we will mention the
detail of such a study in the results and wewill conduct a sensitivity
analysis to assess the validity of the data. In cross-over trials, we
will consider each part of the study as a parallel arm if a washout
period was conducted.
Dealing with missing data
In the first instance, authors will be contacted to provide missing
data or clarification of data from included studies (e.g. when a
study is identified as an abstract only). Missing data and drop-outs
or attrition or both will be assessed for each included study, and
the extent to which the results/conclusions of the review could be
altered by the missing data will be assessed and discussed.
Assessment of heterogeneity
Clinical heterogeneity will be assessed by comparing the distri-
bution of important participant factors between trials (e.g. ad-
ministered dose of drugs, duration of administration of all three
drugs), and trial factors (randomization concealment, blinding of
outcome assessment, losses to follow-up, treatment type, coint-
erventions). Within- and between-study heterogeneity will be as-
sessed using Cochran’s Q-statistic and the heterogeneity test will
be used to assess the null hypothesis that all studies evaluated the
same effect. The effect of heterogeneity is quantified using the I2
statistic which provides a measure of the degree of inconsistency
between studies. If we identify substantial heterogeneity, we will
explore it with the prespecified subgroup analysis. We will assess
heterogeneity by the I2 statistic where values of 0% to 40%, 30%
to 60%, 50% to 90%, and 75% to 100% will be considered as
representing low, moderate, substantial and high level of hetero-
geneity, respectively.
Assessment of reporting biases
Funnel plots (estimated differences in treatment effects against
their standard error) will be drawn if sufficient (10 ormore) studies
are found.Wewill perform a statistical test of the funnel plot using
this approach (Egger Test).
Data synthesis
In order to be able to combine the results, we will consider some
possible differences before performing themeta-analysis. For qual-
itative evidence, we will create a summary table of reviewed studies
using the GRADEpro software.
Wewill provide data regarding study type, comparison, study qual-
ity and number of participants involved. We will create a forest
plot of themeta-analysis for quantitative synthesis.Wewill include
different comparators (placebo or other active comparators such
as H2-receptor antagonists, or prokinetics). However, we will sep-
arate studies with different comparators into different subgroups
for their analysis. For quantification of calculations, a meta anal-
ysis will be performed using RevMan 5 (RevMan 2012). We will
use appropriate statistical methods (Curtin 2002) to combine the
parallel and cross-over trials. A summary statistic will be calculated
for each trial in order to describe the observed intervention effect.
For dichotomous outcomes, we will calculate a RR and for con-
tinuous data we will calculate a MD. When different instruments
have been used, we will use the SMD.
We will calculate a summary (pooled) intervention effect estimate
as a weighted average of the intervention effects estimated in the
individual studies.Wewill choose theweights to reflect the amount
of information that each study contains. A random-effects model
will be used. Meta-regression or sub-group analysis will be used in
the case of statistical heterogeneity. We will perform analyses with
a fixed-effect model in order to test for heterogeneity. P values less
than 0.05 will be considered statistically significant. All statistical
tests will be two-sided.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses to reveal any
effect that might explain any heterogeneity:
1. People suffering from functional dyspepsia according to
different definitions (e.g. Rome III, Rome II criteria) (ROME
criteria).
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2. People suffering from functional dyspepsia by category
subtype (e.g. epigastric pain type versus postprandial distress
type).
3. Treatment duration (less than four weeks versus greater
than four weeks).
4. Dose (standard dose versus low dose; table of standard
doses).
5. Naive versus treatment-experienced.
6. Geographical location (e.g. Western versus Asian studies).
7. Trial funding sources (industry-sponsored versus
nonindustry-sponsored studies).
8. Different control groups (placebo, H2-receptor antagonists,
antacids, prokinetics).
Sensitivity analysis
Sensitivity analyses will be conducted to assess the impact of the
study quality. A sensitivity analysis compares studies fulfilling the
’quality’ criteria compared to the inclusion of all studies regardless
of quality and asks the question, ’Are the findings robust to the
decisions made in the process of obtaining them?’ This involves
the removal of studies that meet certain criteria (e.g. poor-quality,
commercial sponsorship, conference abstract) to determine the ef-
fect of their inclusion on the overall result. This will be undertaken
by including:
1. Only those with low risk of selection bias (associated with
sequence generation or allocation concealment);
2. Only those with low risk of performance bias (associated
with issues of blinding);
3. Only those with low risk of attrition bias (associated with
completeness of data).
4. Fixed-effect versus random-effects models.
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
1. MeSH descriptor: [Dyspepsia] explode all trees
2. dyspep* or “NUD” or “FD”:ti,ab,kw (Word variations have been searched)
3. indigestion or indigestive:ti,ab,kw (Word variations have been searched)
4.#1 or #2 or #3
5. MeSH descriptor: [Antacids] explode all trees
6. antacid* or alkalinizing agent* or antigastralgic agent*:ti,ab,kw (Word variations have been
searched)
7. aluminum or aldrox or algeldrate or alhydrogel or alugel or amphojel or basalgel or brasivil or
dialume or nephrox or pepsamer or rocgel:ti,ab,kw (Word variations have been searched)
8. calcium carbonate or aragonite or calcite or calcium milk or Chalk or limestone or marble or
vaterite:ti,ab,kw (Word variations have been searched)
9. magnesium or brucite or magnesia:ti,ab,kw (Word variations have been searched)
10. aceglutamide aluminum or alexitol sodium or algicon or Almagate or almagel or alubifar or
alugastrin or andursil or attapulgite or bicarbonate or carbex or dihydroxyaluminum sodium
carbonate or gaviscon or hydrotalcite or magaldrate or Mylanta or novaluzid or rennie or solugastril
or titralac or vangatalcite:ti,ab,kw (Word variations have been searched)
11. MeSH descriptor: [Sucralfate] explode all trees
12. (gastro* or gastric or stomach) and mucosa* and protect* and (agent* or drug* or medicine* or
medication*):ti,ab,kw (Word variations have been searched)
13. sucralfate or sulfate or antepsin or carafate or ulcerban or ulcogant or ulsanic:ti,ab,kw (Word
variations have been searched)
14. adopilon or alsucral or sulphate or alusac or andapsin or bisma or dolisec or exinol or hexagastron
or inpepsa or iselpin or keal or melicide or musin or neciblok or peptonorm or succosa or
sucrabest or sucralbene or sucralfin or sucramal or sulcran or sulcrate or treceptan or ufarene or
ulcar or ulcekon or ulcerimin or ulcerlmin or ulcertec orulcogant or ulcyte or ulsaheal or ulsanic or
ulsicral or ulsidex forte or unival or urbal or venter:ti,ab,kw (Word variations have been searched)
adopilon or alsucral or sulphate or alusac or andapsin or bisma or dolisec or exinol or hexagastron
or inpepsa or iselpin or keal or melicide or musin or neciblok or peptonorm or succosa or
sucrabest or sucralbene or sucralfin or sucramal or sulcran or sulcrate or treceptan or ufarene or
ulcar or ulcekon or ulcerimin or ulcerlmin or ulcertec orulcogant or ulcyte or ulsaheal or ulsanic or
ulsicral or ulsidex forte or unival or urbal or venter:ti,ab,kw (Word variations have been searched)
15. bismuth*:ti,ab,kw (Word variations have been searched)
16. #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15
17. #4 and #16
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Appendix 2. MEDLINE search strategy
1. exp Dyspepsia/
2. (dyspep* or “NUD” or “FD”).tw,kw.
3. (indigestion or indigestive).tw,kw.
4. or/1-3
5. exp Antacids/
6. (antacid* or alkalinizing agent* or antigastralgic agent*).tw,kw.
7. (aluminum or aldrox or algeldrate or alhydrogel or alugel or amphojel or basalgel or brasivil
or dialume or nephrox or pepsamer or rocgel).tw,kw.
8. (calcium carbonate or aragonite or calcite or calcium milk or Chalk or limestone or marble
or vaterite).tw,kw.
9. (magnesium or brucite or magnesia).tw,kw.
10. (aceglutamide aluminum or alexitol sodium or algicon or Almagate or almagel or alubifar or
alugastrin or andursil or attapulgite or bicarbonate or carbex or dihydroxyaluminum sodium
carbonate or gaviscon or hydrotalcite or magaldrate or Mylanta or novaluzid or rennie or
solugastril or titralac or vangatalcite).tw,kw.
11. exp Sucralfate/
12. ((gastro* or gastric or stomach) and mucosa* and protect* and (agent* or drug* or
medicine* or medication*)).tw,kw.
13.(sucralfate or sulfate or antepsin or carafate or ulcerban or ulcogant or ulsanic).tw,kw.
Appendix 3. EMBASE search strategy
1. exp Dyspepsia/
2. (dyspep* or “NUD” or “FD”).tw,kw.
3. (indigestion or indigestive).tw,kw.
4. or/1-3
5. exp antacid agent/
6. (antacid* or alkalinizing agent* or antigastralgic agent*).tw,kw.
7. (aluminum or aldrox or algeldrate or alhydrogel or alugel or amphojel or basalgel or brasivil or
dialume or nephrox or pepsamer or rocgel).tw,kw.
8. (calcium carbonate or aragonite or calcite or calcium milk or Chalk or limestone or marble or
vaterite).tw,kw.
9. (magnesium or brucite or magnesia).tw,kw.
10. (aceglutamide aluminum or alexitol sodium or algicon or Almagate or almagel or alubifar or
alugastrin or andursil or attapulgite or bicarbonate or carbex or dihydroxyaluminum sodium
carbonate or gaviscon or hydrotalcite or magaldrate or Mylanta or novaluzid or rennie or
solugastril or titralac or vangatalcite).tw,kw.
11. exp gastrointestinal mucosa protective agent/
12. ((gastro* or gastric or stomach) and mucosa* and protect* and (agent* or drug* or medicine* or
medication*)).tw,kw.
13. (sucralfate or sulfate or antepsin or carafate or ulcerban or ulcogant or ulsanic).tw,kw.
14. (adopilon or alsucral or sulphate or alusac or andapsin or bisma or dolisec or exinol or
hexagastron or inpepsa or iselpin or keal or melicide or musin or neciblok or peptonorm or
succosa or sucrabest or sucralbene or sucralfin or sucramal or sulcran or sulcrate or treceptan
or ufarene or ulcar or ulcekon or ulcerimin or ulcerlmin or ulcertec orulcogant or ulcyte or




18. 4 and 17
19. random*.mp.
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20. placebo:.mp.
21. clinical trial:.mp.
22. double-blind:.mp. or blind:.tw.
23. exp health care quality/
24. or/19-23
25. exp animal/ not human/
26. 24 not 25
27. 18 and 24
Appendix 4. Plain language glossary of terms
Anatomical - relating to bodily structure
Angiogenesis - the formation of different blood vessels
Chronic - long-term
Dyspepsia - indigestion
Dysmotility - a condition in which muscles of the digestive system become impaired and changes in the speed, strength or coordination
in the digestive organs occurs
Epigastric - over the stomach
Endoscopy- A procedure in which a hollow tube with a camera on the end is passed through a hollow organ or tube in the body to
allow visual inspection or the passage of small surgical instruments
Eradication - destruction
Gastric - stomach related
Gastroduodenal dysmotility
Gastroenteritis - inflammation of the lining of the stomach and intestines
Gastrointestinal - relating to the stomach and intestines
Gastroscopy - an examination of the upper digestive tract using a long, thin, flexible tube containing a camera and a light to view the
lining of these organs
H2-recepter antagonists - a type of antacid
Helicobacter pylori - a form of bacteria associated with stomach and duodenal (the first part of the small intestine) ulcers
Hypersensitivity - an excessive or abnormal sensitivity to a substance
Hypochondriasis - the fear of having a serious illness despite not having the condition
Modalities - methods
Motility - a term used to describe the contraction of the muscles that mix and propel contents in the gastrointestinal tract
Neurotoxicity - damage to the brain and nervous system by a poisonous substance
Pathophysiology - the abnormal physical states that accompany a disease
Peptic - relating to digestion
Pepsin - a substance in the stomach that breaks down proteins
Pharmacological - drug related
Polymorphisms - occurring in several different forms
Postprandial - occurring after a meal
Proton pump inhibitors - medications which reduce stomach acid
Psychological - related to a person’s mental or emotional state
Satiation - the sensation of having eaten too much
Visceral - the internal organs of the body, specifically those within the chest (as the heart or lungs) or abdomen (as the liver, pancreas
or intestines)
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